| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| nintedanib | fibroblast growth factor receptor 1 | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.34 | approved | inhibitor |
| nintedanib | fibroblast growth factor receptor 2 | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.53 | approved | inhibitor |
| nintedanib | fibroblast growth factor receptor 3 | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.44 | approved | inhibitor |
| nintedanib | vascular endothelial growth factor receptor 1 | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.25 | approved | inhibitor |
| nintedanib | receptor-type tyrosine-protein kinase flt3 | small molecule | NA | drugbank | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
NA | approved | inhibitor |
| nintedanib | vascular endothelial growth factor receptor 3 | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.24 | approved | inhibitor |
| nintedanib | vascular endothelial growth factor receptor 2 | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.2 | approved | inhibitor |
| nintedanib | tyrosine-protein kinase lck | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.15 | approved | inhibitor |
| nintedanib | tyrosine-protein kinase lyn | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.21 | approved | inhibitor |
| nintedanib | platelet-derived growth factor receptor alpha | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.32 | approved | inhibitor |
| nintedanib | platelet-derived growth factor receptor beta | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.27 | approved | inhibitor |
| nintedanib | proto-oncogene tyrosine-protein kinase src | small molecule | NA | drugbank , DGIDB | Adenocarcinoma[MeSHID:D000230] Idiopathic Pulmonary Fibrosis[MeSHID:D054990] Systemic Scleroderma[MeSHID:D012595] Lung[MeSHID:D008168] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Hamman-Rich syndrome[MeSHID:D011658] Recurrence (disease attribute)[MeSHID:D012008] Pneumonia Interstitial[MeSHID:D017563] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] |
0.15 | approved | inhibitor |
| click here to return to the previous page | ||||||||